You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Biological Decontamination for Forward-Deployed Airbase Using Low Temperature Air Plasmas

    SBC: ASI TECHNOLOGY CORP.            Topic: N/A

    "ASI's plasma consultant, Igor Alexeff, PhD, has invented, tested and patented an atmospheric pressure, dc of 60 Hz AC discharge, that has been operated in air, helium, argon and nitrogen. The apparatus has in laboratory testing successfully destroyedmicroorganisms. The apparatus does not require a complicated, fragile RF power supply for operation. We propose it to be developed into equipment for ...

    STTR Phase I 2002 Department of DefenseAir Force
  2. Development and Application of the High Bandwidth Powered Resonance Tube

    SBC: INNOVATIVE TECH APPLICATIONS LLC            Topic: N/A

    "The proposed Phase 2 program focuses on the development of Powered Resonance Tube (PRT) actuators for application to Active Flow Control (AFC). For effective control across the full operating envelope of an air vehicle, high bandwidth and authority arerequired. In Phase 1, a new variable-frequency PRT actuator concept was developed and its feasibility was demonstrated. In Phase 2, the new actu ...

    STTR Phase II 2002 Department of DefenseAir Force
  3. Flight Demonstration of Stealthy Closed-Loop Attitude Control

    SBC: INNOVATIVE TECH APPLICATIONS LLC            Topic: N/A

    "Flight demonstration of modern stealthy aircraft with an active flow control system is an important, complex, and challenging opportunity. The probability of success is maximized by a progressive plan in which complexity is introduced gradually. Wepropose a plan that includes flight testing of a simple system in Phase I and progressing to a multi-axis demonstration in Phase II. The proposed pr ...

    STTR Phase I 2002 Department of DefenseAir Force
  4. Aero-Optic Distortion Minimization using Active Flow Control

    SBC: INNOVATIVE TECH APPLICATIONS LLC            Topic: N/A

    "A system that integrates the use of zero frequency and high frequency flow control is proposed to reduce aero-optic distortions by minimizing large-scale shear layer structures. An important measure of performance for a tactical laser system is theintensity of the beam on a target. The performance of these systems is degraded by index of refraction variations introduced by large-scale flow stru ...

    STTR Phase I 2002 Department of DefenseAir Force
  5. NEW INOTROPIC AGENTS FOR THE TREATMENT OF HEART FAILURE

    SBC: RELIABLE BIOPHARMACEUTICAL CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of the project is to develop new positive inotropes, represented by specifically modified AMP molecules. All of the currently available positive inotropic agents have significant adverse effects with digitalis being the only orally available positive inotrope. ATP causes a pronounced positive inotropic effect. Receptors for ATP, known as P2 purinergic ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  6. ADENOVIRUS REPLICATION-COMPETENT ANTI-CANCER VECTOR

    SBC: VIRRX, INC            Topic: N/A

    DESCRIPTION (provided by applicant): We have developed several tumor-specific and tissue-specific replication-competent adenoviruses (Ad) vectors for cancer gene therapy. One vector, named KD3, has a mutation in the E1A gene such that KD3 cannot replicate in, and destroy, "normal" cells. However, KD3 can replicate in cancer cells because they have a microenvironment conducive to KD3 replication. ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  7. ADENOVIRUS REPLICATION-COMPETENT ANTI-CANCER VECTOR

    SBC: VIRRX, INC            Topic: N/A

    DESCRIPTION (provided by applicant): We have developed several tumor-specific and tissue-specific replication-competent adenoviruses (Ad) vectors for cancer gene therapy. One vector, named KD3, has a mutation in the E1A gene such that KD3 cannot replicate in, and destroy, "normal" cells. However, KD3 can replicate in cancer cells because they have a microenvironment conducive to KD3 replication. ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  8. Tiptuximab Immunotherapeutic for Cancer

    SBC: Medical Guidance Systems LLC            Topic: NCI

    ? DESCRIPTION (provided by applicant): Poor prognosis cancers such as lung cancer, glioblastoma, pancreatic cancer and others have 3 year survival rates that range from 1%-15%. Recent advancements in the development of therapeutic antibodies haveshown promise in other cancers such as breast, head and neck, and colon cancer. The limitations in antibody development are the paucity of cancer ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government